HEALTH TECHNOLOGY

Tegria Acquires KenSci in Order to Assist Healthcare Organizations in Gaining New Insights from Data

Tegria | June 28, 2021

Tegria announced today the purchase of KenSci, a leader in artificial intelligence systems and healthcare applications with origins in Microsoft's Azure4Research program and the University of Washington.

 

KenSci, which was founded in 2015, has received recognition for its AI platform and solutions that integrate the latest descriptive and predictive analytics technology, assisting healthcare organizations in modernizing their workflows and powering a digital, data-driven, value-based healthcare system. Customers of KenSci, which include providers, payers, and medical device manufacturers, are using advanced analytics and artificial intelligence in their operational, clinical, and care workflows, thus enhancing care experiences and health outcomes. KenSci applications are based on responsible and explainable AI models that aid in making healthcare more efficient, fair, and accountable.

 

Its services are cloud-based and built on Microsoft Azure. Customers of KenSci have also benefitted from the company's strong relationships with industry leaders. In 2020, Microsoft honored KenSci, its US Healthcare Partner of the Year.

 

"Unlocking data to provide insights is the key to making healthcare better for everyone," said Wasif Rasheed, Providence's chief revenue and growth officer. Tegria is set to debut in October 2020. "KenSci has been assisting clients in getting more out of their data for many years, and they understand the critical roles that innovation and collaboration play in accelerating change across all aspects of care. KenSci, when combined with Tegria's industry expertise and a wide variety of solutions, has the potential to have a significant effect on healthcare worldwide. KenSci has arrived in Tegria, and we couldn't be happier."

 

KenSci's AI-powered platform draws insights from data, resulting in improved patient experiences, more accurate diagnoses, and more efficient processes. KenSci automates data preparation across many sources, including real-time and unstructured data, and maps it into the industry-standard schema, preparing it for machine learning models. KenSci's platform is also designed to be versatile and customizable, allowing clients to build their applications.

 

"If you can predict, you have the potential to influence and enhance health outcomes," stated Sudarshan Chitre, CEO of KenSci. "AI and advanced analytics technologies are changing how healthcare companies use data to enhance human health and care outcomes. Tegria will allow us to expedite this transition on a larger scale while also providing instant value to our clients via AI-driven insights. We are thrilled to be joining Tegria so that we may write the next chapter together."

 

KenSci's technology is supported by substantial peer-reviewed research published by The Institute of Electrical and Electronics Engineers (IEEE), The Association for Computing Machinery (ACM), The American Medical Informatics Association (AMIA), and other organizations. KenSci received HIMSS Health Innovation Awards in 2018 and 2019 and KLAS top ratings in healthcare AI in 2019 and 2020. KenSci was a Gartner Cool Vendor and a CMS AI Challenge finalist in 2019. KenSci is headquartered in Seattle and has offices in Singapore and India.

 

With KenSci, Tegria can expand the breadth and depth in electronic health record optimization, managed services, revenue cycle management, and other areas. KenSci will continue to serve its existing client base while also working with its new colleagues on integrated solutions for the global healthcare industry.

 

Tegria's financial advisor was Cascadia Capital, and its legal counsel was McDermott Will & Emery on this deal. Brentwood Capital Advisors served as the exclusive financial adviser for KenSci, while Wilson Sonsini Goodrich & Rosati acted as legal counsel.

 

About Tegria

Tegria, founded by Providence, is dedicated to creating health for a better world. Tegria assists healthcare organizations of all sizes in accelerating technological, clinical, and operational advancements that enable people to live the healthiest lifestyles possible. Tegria is a Seattle-based company with employees throughout the United States and internationally. It employs over 3,000 strategists, technologists, service providers, and scientists committed to providing value to customers.

Spotlight

GTH Pro is the first smartwatch in the world to feature the Arty Heart Health analytics platform, incorporating Arty Score, eCAP® (Exercise Capacity®), ArtyAge™, HSX™, (Heart Stress Index), and TruHR®. TicWatch GTH Pro features Dual-Sensor technology that enables personalized AI-based insights and guidance into arterial and heart health. TicWatch GTH Pro’s Dual PPG Bio Sensors provide unique insights into arterial health and other biometrics specific to the user through high-fidelity sensing points both on the wrist and through the fingertip.


Other News
FUTURE OF HEALTHCARE

Tebra CTO Kyle Ryan Named to the Healthcare Technology Report’s List of Top Healthcare Technology CTOs of 2022

Tebra | November 22, 2022

Tebra, a leader in practice growth technology and cloud-based clinical and financial software, announced that its Chief Technology Officer Kyle Ryan was named in the Healthcare Technology Report’s list of Top 25 Healthcare Technology CTOs of 2022. The annual list recognizes the most accomplished executives in healthcare technology who are leading teams in delivering cutting edge products that boost operations and improve efficiency for their customers. The CTOs on this year’s list have a wide range of impressive backgrounds, but each is the driving force behind their company’s technology innovations, ensuring software functionality and effectiveness. Read the full report here. “Kyle has been an integral part of the executive leadership team at Tebra and has built a strong partnership between product management and the technology team within the organization. He has vast knowledge about healthcare IT and how it applies to solving business problems and is keenly customer focused and is always taking time to understand customer needs at a deeper level. Kyle’s an outstanding ambassador for the company and prides himself on developing a healthy and high-performance culture.” Dan Rodrigues, CEO of Tebra Kyle is responsible for all areas of technology with a focus on the vision and strategy for Tebra’s suite of products and services. He believes that great products are created through a keen customer focus, groundbreaking ideas, precise engineering, and efficient execution. “I am honored to be included in this list of prestigious technology leaders,” Kyle said. “This recognition also highlights the technology team’s passion for improving healthcare and the company’s mission of providing independent practices with digital tools and support to thrive in a new era of healthcare.” About Tebra In 2021, with a combined mission to unlock better healthcare, Kareo and PatientPop joined forces to form Tebra — the operating system for the connected practice of the future. With an all-in-one, purpose-built platform to drive practice success and modernize every step of the patient journey, Tebra provides digital tools and support to attract new patients, deliver modern care, get paid quickly, and operate efficiently.

Read More

MEDICAL DEVICES

Carestream Health Unveils New X-ray Detectors, Enhanced X-ray Rooms at World’s Largest Radiology Exhibition

Carestream Health | November 29, 2022

Carestream’s legacy of delivering quality medical imaging technology continues with the launch of new digital X-ray detectors that help improve clinical outcomes, while enhancements to its existing product portfolio reflect the company’s deep understanding of the radiology profession. At the annual meeting of the Radiological Society of North America (RSNA) in Chicago, the company is displaying its expanding portfolio of medical imaging systems that provide quantifiable benefits to healthcare organizations and their patients, including New Carestream Focus HD 35 and Focus HD 43 detectors that offer higher resolution with a 100 micron pixel pitch that allows for image magnification for better visibility of small objects and microstructures. The detectors’ Cesium (CsI) scintillator is ideal for dose-sensitive pediatric patients; and the detectors have an IP56 rating for better protection against dust and fluid ingress. Next generation of long-length imaging, the Carestream DRX-LC Detector (INVESTIGATIONAL – NOT AVAILABLE FOR COMMERCIAL SALE) captures long-bone and spine images with a single exposure, making it ideal for pediatric imaging and long-bone and spine images of people with limited mobility. In contrast, the traditional multi-shot approach requires three to five exposures followed by manipulation and stitching of the images. The new detector is designed to capture the full image in a single exposure to minimize dose and mitigate motion artifact that can appear from patient movement with a multi-shot exam. The DRX-LC Detector is designed with X-Factor so the detector can be shared across different Carestream X-ray systems and is compatible with both rooms and mobile units. Enhancements to the Carestream DRX-Evolution Plus that provide improved patient comfort and a better ergonomic experience along with improved workflow for the radiographer. Its new tabletop design eliminates rails that can cause strain and discomfort for both radiographer and patient, enabling patients to be moved more smoothly and with less effort to the exam table. New features in the Carestream DRX-Excel Plus provide a better staff experience with faster workflow and better diagnostic image quality. Designed specifically for large and mid-size hospitals and medical centers, this innovative system combines fluoroscopy and general radiology capabilities in one compact unit. It delivers accelerated workflow, high-resolution images and a wide range of patient exam options. “Our commitment to quickly respond to the needs of the radiology community with ideas that clearly work is as strong as ever, and we are solidly positioned to continue developing solutions that have quantifiable benefits to our customers and their patients. Organizations can have complete confidence in our ability to provide high-value technology that helps lower costs, and improves imaging workflow for radiology departments, technologists and other healthcare professionals—all with the goal of improving patient care.” David C. Westgate, Chairman, President and CEO of Carestream About Carestream Health Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic and other applications—all backed by a global service and support network.

Read More

FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Juno Medical Raises $12M Series A Led by NEXT VENTURES and Serena Ventures; Funding Will Fuel Juno's National Expansion

Juno Medical | December 12, 2022

Juno Medical, the modern doctor's office that's designed for the 99%, today announced $12 million in Series A funding co-led by Julian Eison, Managing Partner at NEXT VENTURES, and Serena Williams, Managing Partner at Serena Ventures. Juno’s comprehensive tech-enabled healthcare model is designed to meet the everyday healthcare needs of "the 99%,” with a specific focus on revitalizing neighborhoods across the United States and delivering a beautiful environment, transparent pricing, and exceptional care. The funding will support Juno’s continued development of its technology platform and expansion into new markets, including Atlanta, Georgia, Tulsa, Oklahoma, and Los Angeles, California. Other notable participants include Vast Ventures, which led Juno’s seed round, Empire State Development’s New York Ventures, TXV Partners, Genius Guild, Gaingels, and previous investors Atento Capital and Humbition. Juno’s team has unmatched healthcare, technology, and business expertise. Juno Founder and CEO Dr. Akili Hinson’s background spans medicine and business. He is a physician by training and former McKinsey & Company consultant with expertise in payment innovation, value-based care delivery, and digital transformation. Juno’s medical leadership team includes Chief Health Officer Dr. Aarti Agarwal, an internist and epidemiologist with expertise in global health and value-based care, as well as Juno’s two founding physicians, Dr. Shante Hinson, a rheumatologist and preventative health expert dedicated to bridging the healthcare gap in underserved communities, and Dr. Candice Fraser, an OB/GYN with over a decade of experience as a trusted guide in women's health. “Juno’s vision is to reimagine the future of healthcare by finally making exceptional, family-centered care accessible and affordable for the 99% all across the United States. At Juno, we’ve designed healthcare that people love by providing the highest quality care and incredible service in a beautiful environment that feels like a place to belong—all powered by modern technology. We are honored by the support of the thousands of patients who have trusted us with their care and our investors who believe in us — we could not be more excited to bring Juno to more neighborhoods and communities all across the country.” Dr. Akili Hinson Juno’s products and services are designed for the family’s “Chief Caregiver” by bringing the best of primary care, pediatrics, women's health, same-day care, and virtual care into one thoughtfully designed experience. “It brings joy to my heart knowing Juno is on a mission to bring exceptional healthcare to cities and developing areas of our nation where suboptimal care, facilities, and services have been tolerated out of necessity for way too long," said Julian Eison, Managing Partner of NEXT VENTURES. “I believe Juno’s hybrid approach leveraging brick and mortar clinics paired with digital access is an enduring model that will serve as the fundamental basis to build community trust and outcomes to match. It’s an honor to have partnered with such an esteemed team, attacking one of the largest problems of our time.” Juno accelerated the opening of its first location in the Harlem neighborhood of New York City to see patients in April 2020 when the COVID-19 pandemic devastated New York and many physician offices were closed. In addition to providing COVID testing and care to hundreds of residents, Juno continued to offer in-person preventive care during the pandemic which led to the identification of treatable cancers and previously undiagnosed chronic conditions in asymptomatic women and men — which may have been missed in the absence of the founding team’s commitment to serve. “We are honored to partner with Juno to expand upon their inclusive, full-service healthcare home model where people from all backgrounds feel seen, heard and welcome,” said Serena Williams, Managing Partner of Serena Ventures. “There is a serious need to address equity issues in healthcare, mental health and wellness services that many communities face. Juno and its talented team have the vision, model and track record to disrupt the unacceptable status quo in healthcare.” Juno’s approach and presence in underserved communities is part of the solution to a growing challenge of healthcare disparities that exist across the United States. A recent report from the Kaiser Family Foundation outlined race-based disparities in maternal and infant health and mortality. The markets in which Juno will expand have their own unique health care challenges. On November 1, Atlanta Medical Center closed its doors, leaving an already-strained healthcare system with one less option and exacerbating concerns about the future of safety net hospitals in the region and state. In North Tulsa, where Juno’s clinic will be located, residents have a life expectancy 13 years shorter than their neighbors in South Tulsa. “Empire State Development’s New York Ventures exists to partner with promising startups that are working to solve the world’s most important challenges, and we are proud to support Juno Medical as they strive to provide exceptional healthcare to New Yorkers, especially in areas that are often overlooked or left behind,” said Hope Knight, President, CEO and Commissioner of Empire State Development. “Juno’s success in New York State is a road map for the future and a proven model for delivering quality, affordable healthcare for all.” Unlike recent trends in concierge medicine and digital health, Juno’s model is designed to work with nearly all types of insurance—including commercial plans, Medicare and Medicaid—without initial barriers or exclusive membership fees. Juno is taking a different approach to meet the needs of busy households by offering additional plans that start at $20 per month per person or $50 per month per family that complement its core services with added conveniences like night and weekend appointments, savings, and unique events and experiences. Juno’s hybrid model includes both in-person options for patients and a robust e-health platform, which includes an app that allows patients to make appointments, manage care information, and keep in touch with their care team. As part of its mission to create a healthier world, Juno will use this funding to expand into new markets and recruit the highest-caliber provider talent in Atlanta, Tulsa and Los Angeles. Juno’s new clinics will be located in the historic yet overlooked neighborhoods of East Atlanta, Greenwood (Tulsa), and Inglewood (Los Angeles). The funding will also support the continued expansion of Juno’s robust technology platform for both patients and healthcare providers—a critical component of Juno’s innovative model. About Juno Medical Launched in April 2020, Juno Medical is a tech-enabled healthcare service provider designed for you and yours. The company offers exceptional hospitality, modern technology, and transparent prices that won't break the bank and brings the best of adult primary care, pediatrics, women's health, and same-day care into one thoughtful and beautifully designed place.

Read More

FUTURE OF HEALTHCARE

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

Abbott | November 21, 2022

Abbott has been recognized by the Consumer Technology Association with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show the most influential technology event in the world. Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards, all within the Digital Health award category Aveir VR Leadless Pacemaker – The world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable. The system was developed by Abbott to treat patients with slow heart rhythms and eliminates wires used to deliver therapy in traditional pacemakers. Proclaim Plus SCS System – Abbott's latest advancement in neurostimulation therapy to treat chronic pain using low doses of targeted BurstDR™ stimulation that can be adjusted as a person's therapeutic needs evolve across up to six areas of the body, which is more pain sites in the body than ever before. Alinity m Monkeypox PCR test1 – A first of its kind, Abbott received FDA Emergency Use Authorization of its PCR test for detecting the monkeypox virus. The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products. The program recognizes the year's most innovative products in a multitude of consumer technology product categories and distinguishes the highest-rated in each. Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years. Other Abbott products previously honored with CES Innovation Awards include FreeStyle Libre 32, the world's smallest, thinnest3 and most accurate4 14-day glucose sensor and a CES 2022 Best of Innovation Award winner; BinaxNOW™5, the #1 COVID-19 self test in the U.S.; and the UltreonTM 1.0 intravascular imaging and coronary physiology software platform, which helps guide and optimize stenting decisions, combining optical coherence tomography with artificial intelligence. In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation. The FreeStyle Libre portfolio has transformed the lives of approximately 4.5 million people6 living with diabetes globally. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.

Read More

Spotlight

GTH Pro is the first smartwatch in the world to feature the Arty Heart Health analytics platform, incorporating Arty Score, eCAP® (Exercise Capacity®), ArtyAge™, HSX™, (Heart Stress Index), and TruHR®. TicWatch GTH Pro features Dual-Sensor technology that enables personalized AI-based insights and guidance into arterial and heart health. TicWatch GTH Pro’s Dual PPG Bio Sensors provide unique insights into arterial health and other biometrics specific to the user through high-fidelity sensing points both on the wrist and through the fingertip.

Resources